Rosiglitazone or pioglitazone in type 2 diabetes?

被引：6
|
作者：
de Vries, Corinne S. [1 ]
Russell-Jones, David L. [2 ]
机构：
[1] Univ Bath, Dept Pharm & Pharmacol, Bath BA2 7AY, Avon, England
[2] Univ Surrey, Ctr Diabet Endocrinol & Res, Guildford GU2 7XX, Surrey, England
来源：
BRITISH MEDICAL JOURNAL | 2009年 / 339卷
关键词：
CONGESTIVE-HEART-FAILURE; THIAZOLIDINEDIONE USE; CARDIOVASCULAR DEATH; RISK; MORTALITY;
D O I：
10.1136/bmj.b3076
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页数：3
相关论文
共 50 条
  • [1] Dyslipidaemia in Type 2 diabetes: effects of the thiazolidinediones pioglitazone and rosiglitazone
    Mukhtar, R
    Reckless, JPD
    [J]. DIABETIC MEDICINE, 2005, 22 : 6 - 10
  • [2] Implications of rosiglitazone and pioglitazone on cardiovascular risk in patients with type 2 diabetes mellitus
    Irons, BK
    Greene, RS
    Mazzolini, TA
    Edwards, KL
    Sleeper, RB
    [J]. PHARMACOTHERAPY, 2006, 26 (02): : 168 - 181
  • [3] A comparison of pioglitazone and rosiglitazone for hospitalization for acute myocardial infarction in type 2 diabetes
    Gerrits, Charles M.
    Bhattacharya, Mondira
    Manthena, Shivaji
    Baran, Robert
    Perez, Alfonso
    Kupfer, Stuart
    [J]. PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2007, 16 (12) : 1314 - 1316
  • [4] Rosiglitazone and pioglitazone increase fracture risk in women and men with type 2 diabetes
    Aubert, R. E.
    Herrera, V.
    Chen, W.
    Haffner, S. M.
    Pendergrass, M.
    [J]. DIABETES OBESITY & METABOLISM, 2010, 12 (08): : 716 - 721
  • [5] A comparison of lipid and glycemic effects of pioglitazone and rosiglitazone in patients with type 2 diabetes and dyslipidemia
    Goldberg, RB
    Kendall, DM
    Deeg, MA
    Buse, JB
    Zagar, AJ
    Pinaire, JA
    Tan, MH
    Khan, MA
    Perez, AT
    Jacober, SJ
    [J]. DIABETES CARE, 2005, 28 (07) : 1547 - 1554
  • [6] Comparison of the glycemic effects of rosiglitazone and pioglitazone in triple oral therapy in type 2 diabetes
    Tran, Michael T.
    Navar, Maria D.
    Davidson, Mayer B.
    [J]. DIABETES CARE, 2006, 29 (06) : 1395 - 1396
  • [7] Effects of rosiglitazone and pioglitazone on lipoprotein metabolism in patients with Type 2 diabetes and normal lipids
    Brackenridge, A. L.
    Jackson, N.
    Jefferson, W.
    Stolinski, M.
    Shojaee-Moradie, F.
    Hovorka, R.
    Umpleby, A. M.
    Russell-Jones, D.
    [J]. DIABETIC MEDICINE, 2009, 26 (05) : 532 - 539
  • [8] A comparison of lipid and glycemic effects of pioglitazone and rosiglitazone in patients with type 2 diabetes and dyslipidemia
    Goldberg, RB
    Kendall, DM
    Deeg, MA
    Buse, JB
    Zagar, AJ
    Pinaire, JA
    Tan, MH
    Khan, MA
    Perez, AT
    Jacober, SJ
    [J]. CIRCULATION, 2005, 111 (13) : 1727 - 1728
  • [9] The effect of rosiglitazone and pioglitazone on VLDL apolipoprotein B metabolism in patients with type 2 diabetes
    Brackenridge, AL
    Jackson, N
    Shojaee-Moradie, F
    Umpleby, AM
    Russell-Jones, D
    [J]. DIABETES, 2005, 54 : A234 - A234
  • [10] A pilot study of the effects of pioglitazone and rosiglitazone on de novo lipogenesis in type 2 diabetes
    Beysen, Carine
    Murphy, Elizabeth J.
    Nagaraja, Hirisadarahally
    Decaris, Martin
    Riiff, Timothy
    Fong, Alex
    Hellerstein, Marc K.
    Boyle, Patrick J.
    [J]. JOURNAL OF LIPID RESEARCH, 2008, 49 (12) : 2657 - 2663
12345